Trials / Unknown
UnknownNCT04367948
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the normal physiological distribution of positron nuclide labeled NOTA-F API in human body and its detection efficiency for lymphoma
Detailed description
Subjects first undergo an 18F-FDG test, followed by 68Ga-NOTA-FAPI04 or 18F-NOTA-FAPI04 test in groups.Investigate the standardized uptake value(SUV) of 68Ga/ 18F-NOTA-FAPI04 for the target lesion, the ratio of the standardized uptake value(SUVR) of 68Ga/ 18F-NOTA-FAPI04 for the target lesion within each time window to that of the normal corresponding tissue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-FDG and 68Ga-NOTA-FAPI04 PET/CT | Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time |
| DIAGNOSTIC_TEST | 18F-FDG and 18F-NOTA-FAPI04 PET/CT | Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2021-12-01
- Completion
- 2022-12-01
- First posted
- 2020-04-29
- Last updated
- 2020-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04367948. Inclusion in this directory is not an endorsement.